![Robert Wild](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert Wild
Berater bei
ShangPharma Innovation, Inc.
Profil
Robert Wild was the founder of Dracen Pharmaceuticals, Inc., founded in 2017, where the title held was Chief Scientific Officer & Founding Executive from 2017 to 2023.
Dr. Wild currently holds the position of Executive In Residence at ShangPharma Innovation, Inc. since 2017.
Former jobs include Co-Chief Executive Officer at Azkarra Therapeutics, Inc., Senior Director & Head at OSI Pharmaceuticals, Inc. from 2006 to 2010, Chief Scientific Officer at Eli Lilly & Co., and Chief Scientific Officer & Senior VP-Research at Ignyta, Inc. from 2014 to 2016.
Education includes undergraduate and doctorate degrees from the University of Minnesota, conferred in 1995 and 2000 respectively.
Aktive Positionen von Robert Wild
| Unternehmen | Position | Beginn |
|---|---|---|
ShangPharma Innovation, Inc.
 ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation invests in companies located in the United States. The firm targets companies operating in the fields of healthcare sector. It provides financing for seed to early stage capital requirements. | Berater | 01.03.2017 |
Ehemalige bekannte Positionen von Robert Wild
| Unternehmen | Position | Ende |
|---|---|---|
Azkarra Therapeutics, Inc.
 Azkarra Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapies | Vorstandsvorsitzender | 01.03.2025 |
Dracen Pharmaceuticals, Inc.
 Dracen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Gründer | 01.02.2023 |
| IGNYTA INC | Technik-/Wissenschafts-/F&E-Leiter | 22.02.2016 |
| OSI PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.08.2010 |
| ELI LILLY AND COMPANY | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Robert Wild
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
95
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical drugs | Health Technology |
University of Minnesota
 University of Minnesota Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ignyta, Inc.
 Ignyta, Inc. BiotechnologyHealth Technology Operates as a medicine biotechnology company which provides new drugs services for cancer patients | Health Technology |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation invests in companies located in the United States. The firm targets companies operating in the fields of healthcare sector. It provides financing for seed to early stage capital requirements. | Finance |
Dracen Pharmaceuticals, Inc.
Dracen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
Azkarra Therapeutics, Inc.
Azkarra Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapies | Health Technology |
